Xilio Therapeutics

Xilio Therapeutics is a biotechnology company dedicated to advancing the next generation of cancer immunotherapies, aiming to improve patient outcomes by selectively unleashing the power of the immune system at the tumor site. The company's tumor-selective immunotherapies are based on its proprietary technology, which maximizes the proven efficacy of immuno-oncology therapies and restricts their activity to the tumor to minimize peripheral side effects. The broad applicability of these therapies across cancer types means that all patients can potentially benefit from these therapeutic agents.